1 Remedy for Big Drug Companies

The guest on this week's nationally syndicated Motley Fool Money radio show is Vijay Vaitheeswaran, author of the new book Need, Speed, and Greed: How the New Rules of Innovation Can Transform Businesses, Propel Nations to Greatness, and Tame the World's Most Wicked Problems. In this audio segment, he discusses why major drug companies such as Eli Lilly and Pfizer suffer from having misaligned incentives and how the situation can be remedied.

A health-care stock is just one of the stocks featured in The Motley Fool's brand-new free report, "These Stocks Could Skyrocket After the 2012 President Election." It features four stocks primed to profit following the election (two for a Democratic victory and two for a Republican one). Simply click here -- it's free.

At the time thisarticle was published Chris Hillowns shares of Pfizer.Motley Fool newsletter serviceshave recommended buying shares of Pfizer. The Motley Fool has adisclosure policy. We Fools don't all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. Try any of our Foolish newsletter servicesfree for 30 days.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.